NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report)'s share price fell 5.2% during mid-day trading on Wednesday . The company traded as low as $8.32 and last traded at $8.36. 1,074,987 shares traded hands during mid-day trading, a decline of 46% from the average session volume of 2,006,619 shares. The stock had previously closed at $8.81.
Analysts Set New Price Targets
A number of research firms recently commented on NEO. Piper Sandler set a $11.00 price target on NeoGenomics and gave the stock an "overweight" rating in a research note on Monday, August 4th. Wall Street Zen raised NeoGenomics from a "sell" rating to a "hold" rating in a report on Tuesday, May 13th. Guggenheim began coverage on NeoGenomics in a research report on Thursday, May 15th. They issued a "neutral" rating for the company. Stephens upped their price target on NeoGenomics from $6.50 to $11.00 and gave the company an "overweight" rating in a research report on Tuesday. Finally, BTIG Research reaffirmed a "neutral" rating on shares of NeoGenomics in a report on Wednesday, July 30th. Five equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $13.22.
Get Our Latest Stock Report on NeoGenomics
NeoGenomics Stock Performance
The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.58 and a current ratio of 3.92. The stock has a 50 day moving average of $6.66 and a 200 day moving average of $8.10. The stock has a market capitalization of $1.06 billion, a P/E ratio of -10.10 and a beta of 1.62.
Institutional Trading of NeoGenomics
Hedge funds have recently bought and sold shares of the company. Brooklyn Investment Group bought a new position in NeoGenomics in the 1st quarter worth about $35,000. Headlands Technologies LLC acquired a new position in NeoGenomics during the 2nd quarter worth $32,000. CWM LLC grew its position in NeoGenomics by 42.6% in the 1st quarter. CWM LLC now owns 6,299 shares of the medical research company's stock valued at $60,000 after buying an additional 1,883 shares in the last quarter. AlphaQuest LLC bought a new position in shares of NeoGenomics in the first quarter valued at approximately $60,000. Finally, Moors & Cabot Inc. bought a new position in NeoGenomics during the 1st quarter valued at $95,000. 98.50% of the stock is currently owned by institutional investors.
About NeoGenomics
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
